These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9179183)

  • 21. Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using transrectal 31phosphorus magnetic resonance spectroscopy: a preliminary report.
    Narayan P; Jajodia P; Kurhanewicz J; Thomas A; MacDonald J; Hubesch B; Hedgcock M; Anderson CM; James TL; Tanagho EA
    J Urol; 1991 Jul; 146(1):66-74. PubMed ID: 1711587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.
    Crehange G; Maingon P; Gauthier M; Parfait S; Cochet A; Mirjolet C; Bonnetain F; Cormier L; Brunotte F; Walker P
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e407-13. PubMed ID: 21605949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MR spectroscopy of prostate cancer. Initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Carlani M; Di Roma M; Colangelo V; Simonetti G
    J Exp Clin Cancer Res; 2005 Dec; 24(4):523-30. PubMed ID: 16471314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Technical Note: evaluation of the uncertainties in (choline + creatine)/citrate ratios measured by proton MR spectroscopic imaging in patients suspicious for prostate cancer.
    Zbýň Š; Krššák M; Memarsadeghi M; Gholami B; Haitel A; Weber M; Helbich TH; Trattnig S; Moser E; Gruber S
    Rofo; 2014 Jul; 186(7):698-702. PubMed ID: 24940925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiation of human prostate cancer from benign hypertrophy by in vitro 1H NMR.
    Fowler AH; Pappas AA; Holder JC; Finkbeiner AE; Dalrymple GV; Mullins MS; Sprigg JR; Komoroski RA
    Magn Reson Med; 1992 May; 25(1):140-7. PubMed ID: 1375702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?
    Schmuecking M; Boltze C; Geyer H; Salz H; Schilling B; Wendt TG; Kloetzer KH; Marx C
    Int J Radiat Biol; 2009 Sep; 85(9):814-24. PubMed ID: 19701842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostatic carcinoma and benign prostatic hyperplasia: inability of MR imaging to distinguish between the two diseases.
    Ling D; Lee JK; Heiken JP; Balfe DM; Glazer HS; McClennan BL
    Radiology; 1986 Jan; 158(1):103-7. PubMed ID: 2416005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2D JPRESS of human prostates using an endorectal receiver coil.
    Yue K; Marumoto A; Binesh N; Thomas MA
    Magn Reson Med; 2002 Jun; 47(6):1059-64. PubMed ID: 12111951
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors.
    Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX
    Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Characterization of prostate cancer, benign prostatic hyperplasia and normal prostates using endorectal 1H magnetic resonance spectroscopy].
    Saikawa S; Suzuki Y; Tomoi M; Yoshida M; Ishii Y; Okada K
    Nihon Hinyokika Gakkai Zasshi; 1995 Nov; 86(11):1673-80. PubMed ID: 8551711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results.
    Zakian KL; Eberhardt S; Hricak H; Shukla-Dave A; Kleinman S; Muruganandham M; Sircar K; Kattan MW; Reuter VE; Scardino PT; Koutcher JA
    Radiology; 2003 Oct; 229(1):241-7. PubMed ID: 12920178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation between benign prostatic hyperplasia and prostate cancer in the transitional zone evaluated by 1H magnetic resonance spectroscopic imaging.
    Li SY; Chen M; Wang R; Zhou C
    Chin Med Sci J; 2007 Dec; 22(4):238-42. PubMed ID: 18246671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level.
    Kumar V; Jagannathan NR; Kumar R; Das SC; Jindal L; Thulkar S; Gupta SD; Dwivedi SN; Roell S; Hemal AK; Gupta NP
    Magn Reson Imaging; 2006 Jun; 24(5):541-8. PubMed ID: 16735174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MRI spectroscopy in screening of prostate cancer.
    Goeb K; Engehausen DG; Krause FS; Hollenbach HP; Niedobitek G; Buettner M; Frangou P; Engelhard K
    Anticancer Res; 2007; 27(1B):687-93. PubMed ID: 17348461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolite ratios in 1H MR spectroscopic imaging of the prostate.
    Kobus T; Wright AJ; Weiland E; Heerschap A; Scheenen TW
    Magn Reson Med; 2015 Jan; 73(1):1-12. PubMed ID: 24488656
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
    Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
    J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification.
    Bellomo G; Marcocci F; Bianchini D; Mezzenga E; D'Errico V; Menghi E; Zannoli R; Sarnelli A
    PLoS One; 2016; 11(11):e0165730. PubMed ID: 27832096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer.
    Hasumi M; Suzuki K; Taketomi A; Matsui H; Yamamoto T; Ito K; Kurokawa K; Aoki J; Endo K; Yamanaka H
    Anticancer Res; 2003; 23(5b):4223-7. PubMed ID: 14666629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vivo metabolic characterization of healthy prostate and orthotopic prostate cancer in rats using proton magnetic resonance spectroscopy at 4.7 T.
    Walker P; Provent P; Tizon X; Créhange G; Duchamp O; Brunotte F; Genne P
    Acta Radiol; 2013 Feb; 54(1):121-6. PubMed ID: 23081956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer: a comparative study of 11C-choline PET and MR imaging combined with proton MR spectroscopy.
    Yamaguchi T; Lee J; Uemura H; Sasaki T; Takahashi N; Oka T; Shizukuishi K; Endou H; Kubota Y; Inoue T
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):742-8. PubMed ID: 16052370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.